diabetestalk.net

Januvia Lawsuit Settlement Amounts

Januvia Lawsuits | Recall Report

Januvia Lawsuits | Recall Report

Januvia, and the similar drug Janumet, were developed by Merck & Co. to treat type 2 diabetes. Many pharmaceutical companies have gotten a type 2 diabetes drug on the market in the last decade. These drugs have the potential to be big money makers for the companies because of the increasing rate of diabetes in the U.S. Patients who have taken either of these drugs have reported serious complications and lawsuits have been started claiming that Merck did not adequately warn the public about those risks. Some people have suffered from pancreatitis, pancreatic cancer, and thyroid cancer while taking Januvia or Janumet. If you took either of these drugs and feel that you werent warned about the potential complications you ultimately experienced, you may be in a position to start your own Januvia lawsuit. Januvia is a drug designed to treat type 2 diabetes, a chronic illness associated with dangerously high blood sugar levels. When it is left untreated this type of diabetes can lead to serious complications that eventually become debilitating and life threatening. The U.S. Food and Drug Administration (FDA) approved Januvia in 2006 and Janumet in 2007 for treatment of type 2 diabetes along with lifestyle changes including a healthy diet, exercise, and weight loss. Januvia is the generic drug sitagliptin and Janumet is a combination of sitagliptin and another drug called metformin. Sitagliptin belongs to the class of drugs called dipeptidyl peptidase-4 (DPP-4) inhibitors. These are drugs that inhibit the protein DPP-4. The result of inhibiting it is an increase in insulin production, which regulates blood sugar, and a decrease in the amount of sugar released into the blood by the liver. Janumet attacks high blood sugar levels with two drugs. It contains sitagliptin as well a Continue reading >>

Byetta Settlements Reached In 84 Cases, But Hundreds Of Lawsuits Remain

Byetta Settlements Reached In 84 Cases, But Hundreds Of Lawsuits Remain

Byetta Settlements Reached in 84 Cases, But Hundreds of Lawsuits Remain AstraZeneca indicates that after settling dozens of cases earlier this year, it continues to face more than 400 Byetta lawsuits involving allegations that former users of the diabetes drug developed pancreatic cancer, thyroid cancer or pancreatitis. In a second quarter financial report (PDF) issued last week, AstraZeneca disclosed that Byetta settlement agreements have been reached to resolve at least 84 claims pending in California state court, including one case that was scheduled for trial to begin in February 2014. Other than the resolved cases, the drug maker notes that about 409 lawsuits over Byetta side effects remain in various state and federal courts nationwide. Neither the terms of the settlement agreements or the nature of injuries involved in the claims were disclosed by the drug maker. Many of the remaining cases involve allegations that plaintiffs developed pancreatic cancer from Byetta. All of those lawsuits pending in the federal court system are currently consolidated as part of a multidistrict litigation (MDL), which is centralized before U.S. District Judge Anthony Battaglia in the Southern District of California to reduce duplicative discovery, avoid conflicting pretrial rulings from different judges and to serve the convenience of the parties, witnesses and the courts. The MDL not only includes cases involving Byetta, but also consists of Januvia lawsuits , Janumet lawsuits and Victoza lawsuits where plaintiffs allege they developed pancreatic cancer after taking those similar diabetes medications. According to the latest case list (PDF) released by the U.S. Judicial Panel on Multidistrict Litigation, more than 460 cases are currently pending in the MDL involving the various d Continue reading >>

All About The Januvia And Victoza Pancreatic Cancer Lawsuits

All About The Januvia And Victoza Pancreatic Cancer Lawsuits

The federal court overseeing the nationwide Januvia and Victozia pancreatic cancer litigation appointed Mr. Kennerly to the “Plaintiffs’ Steering Committee,” the group of plaintiffs’ lawyers responsible for building the case against Merck, the manufacturer of Januvia and Janumet, and Novo Nordisk, the manufacturer of Victoza. I’ve written several posts going back to 2012 about the link between Januvia and pancreatic cancer. Below is an brief summary of the science behind the cases. As of January 2018, there are several different groups of Januvia lawsuits: a federal multidistrict litigation based in the federal court in San Diego, a state consolidated litigation in Los Angeles, and scattered lawsuits filed in other states. No jury trials have been held. Correspondingly, there have been no Januvia or Victoza lawsuit settlements: the drug companies still vehemently deny any responsibility, and the litigation is simply too new for any settlement discussions yet. I represent a wide variety of clients who developed pancreatic cancer after taking Januvia, clients on both sides of the country and everywhere in between, clients ranging in age from their forties to their eighties. Our law firm has filed Januvia and Victoza cases in all of the courts identified above, and we are continuing to file cases. We review cases free of charge, and we represent clients on a contingent fee. (That is, we pay all costs on the case, and only charge a fee if we recover compensation.) The Causes Of Pancreatic Cancer, And The Cancer’s Relationship To Diabetes If you’re reading this page, then likely you or someone you know was diagnosed with pancreatic cancer. You already know that the prognosis is typically poor, even with aggressive treatment. Pancreatic cancer is typically asymp Continue reading >>

Byetta, Januvia, And Victoza Diabetes Lawsuit Settlement Funding

Byetta, Januvia, And Victoza Diabetes Lawsuit Settlement Funding

Byetta, Januvia, and Victoza Diabetes Lawsuit Settlement Funding Byetta, Januvia, Victoza Diabetes Drug Cases Legal-Bay LLC, The Lawsuit Settlement Funding Company, is an industry leader in providing lawsuit pre-settlement and settlement funding to families who have been severely injured by the use of Byetta, Januvia, Victoza and other diabetes medication. Legal-Bay is providing large lawsuit cash advances for Byetta, Januvia, and Victoza lawsuits involving Pancreatitis and Pancreatic Cancer. In 2007, The U.S. Food and Drug Administration (FDA) began issuing alerts regarding their concerns of increased risk of acute pancreatitis in patients taking the diabetes drug Byetta. In 2009, the FDA issued a warning on the diabetes drug, Januvia, stating that patients taking Januvia could lead to being diagnosed with Pancreatitis. The alert was issued after the FDA received 88 complaints of patients being diagnosed with pancreatitis after taking Januvia. In 2011, the University of California thoroughly reviewed data compiled by the FDA regarding adverse events and the report indicated that patients that used Byetta or Januvia had 3xs the risk of pancreatic cancer. In 2013, FDA issued another Alert on their website that they were investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes. Lawsuits Being Filed Against Diabetes Drug Makers Byetta, Amylin and Ely Lilly Pharmaceuticals Need Cash Today on Your Byetta, Januvia, or Victoza Lawsuit? If you have already hired a diabetes drug law firm to pursue your claim against one of the manufacturers listed above, and need cash today while you wait for your settlement, Legal-Bay can help you with obtaining up to $50k in pre-settlement lawsu Continue reading >>

Januvia Lawsuit Funding Helps Plaintiffs During Lengthy Litigation

Januvia Lawsuit Funding Helps Plaintiffs During Lengthy Litigation

Januvia Lawsuit Funding Helps Plaintiffs During Lengthy Litigation Litigation for cases alleging injury from Byetta or Januvia can take a very long time, especially for people who are suffering with medical bills and expenses related to being forcibly retired due to sudden injury or disease. The situation can be complicated when there are hundreds or thousands of similar cases appearing in courts across America. For this reason, Januvia lawsuit funding may help plaintiffs bridge the gap until their cases resolve in court. The U.S. Judicial Panel on Multidistrict Litigation will hear oral arguments on July 25to decide whether more than 50 Januvia lawsuits filed in district courts should be centralized before one judge who will coordinate pre-trial hearings. The motion to consolidate lawsuits into MDL began back in April, as cases continued to pour in across the country. Many of the lawsuits arose after a February 25, 2013 study published in the Journal of the American Medical Association revealed that patients taking Byetta or Januvia were twice as likely to end up in the hospital with potentially fatal pancreatitis. Furthermore, a study published in the March issue of Diabetes, the journal of the American Diabetes Association, showed that diabetics had a 40 percent increase in cell changes that could lead to pancreatic cancer among those taking incretin mimetics like Januvia or Byetta. While Mercks Januvia is an oral pill and Bristol-Myers Squibbs Byetta is an injectable medication, they both work by increasing the amounts of GLP-1 hormone, which triggers the pancreas to produce insulin. However, trouble arises when the digestive enzymes are activated before leaving the pancreas, causing the pancreas to digest some of the organ tissue. This causes inflammation, pain, f Continue reading >>

The Science Behind Januvia Lawsuit Settlement Claims

The Science Behind Januvia Lawsuit Settlement Claims

A report published by the Institute for Safe Medication Practices (ISMP) highlighted a high incidence rate of serious pancreas-related injuries related to the use of medications prescribed to treat type 2 diabetes. Several studies have pointed to a possible link between Januvia and pancreatic cancer, leading many patients to file claims in hopes of a Januvia lawsuit settlement . The IMSP report included sitagliptin (marketed as Januvia and Janumet), exenatide (Byetta and Bydureon), and several others drugs. The report, based on adverse events submitted to the Food and Drug Administration, showed a possible connection between Januvia and pancreatic cancer . Januvia has been under increasing scrutiny lately due to concerns of life-threatening side effects. The medical community was alerted years ago that the drug increases the risk of pancreatitis. But most patients are unaware that it could also expose them to pancreatic cancer. The disease has not been added to the drugs safety labeling or prescribing information. However, a growing number of Januvia users who have been diagnosed with cancer have asked attorneys to review potential Januvia lawsuit claims . They allege the manufacturer failed to provide sufficient warning of the danger. In the space below, well discuss data presented in the ISMP report. Well also explain its significance to those who have used GLP-1-based drugs like Januvia. If you or a loved one has developed cancer after using this medication, you may be eligible to file a claim against the manufacturer. ISMP Report Shows Link Between Januvia And Pancreatic Cancer The report profiled 5 medications: sitagliptin, exenatide, linagliptin, saxagliptin, and liraglutide. All of them either mimic the action of an incretin hormone called glucagon-like peptide- Continue reading >>

Januvia Lawsuit

Januvia Lawsuit

Januvia has recently been linked to pancreatitis, pancreatic cancer, and a severe skin disorder known as bullous pemphigoid. Mercks popular type 2 diabetes drug Januvia (generic: sitagliptin) has recently been linked to pancreatitis, pancreatic cancer, and a severe skin disorder known as bullous pemphigoid. Free Confidential Lawsuit Evaluation: If you or a loved one has been diagnosed with pancreatic cancer after taking Januvia, you should contact our law firm immediately . You may be entitled to compensation by filing a suit and our lawyers can help. Update: DPP-4 Inhibitors Linked to Rhabdomyolysis December 1, 2017 Januvia and other type 2 diabetes drugs from the DPP-4 inhibitor class have been linked to reports to a severe muscular disease called rhabdomyolysis, according to the FDA Adverse Event Reporting System (FAERS) . Rhabdomyolysis is as condition in which the skeletal muscle breaks down rapidly, causing symptoms such as fever, nausea, confusion, malaise and dark-colored urine. Manufactured and marketed by Merck & Co., Januvia is a widely-prescribed medication used to help lower blood sugar levels in individuals with type 2 diabetes. The drug works by increasing insulin production in response to food intake and decreasing the amount of sugar that the liver produces. Januvia is part of a class of diabetes medications called dipeptidyl peptidase-4 (DPP-4) inhibitors that break down incretin hormones. As a DPP-4 inhibitor, Januvia slows the breakdown of incretin hormones, thereby increasing the level of these substances in the body. This, in turn, increases insulin production in response to meals and decreases the amount of glucose (sugar) that the liver produces. Januvia was approved by the FDA in October 2006. On September 25, 2009, the FDA notified healthcare Continue reading >>

Januvia Class Action Lawsuit Claims & Cash Settlements Attorneys Ready

Januvia Class Action Lawsuit Claims & Cash Settlements Attorneys Ready

Cases associated with Januivaare acute, and brief. In UCLA, a clinical study discovered that taking Januivaincreases the risk of pancreatitis six-fold, and that cases usually develop in less than two months. Januivais also linked to pancreatic cancer. Pancreatic cancer tumors can grow without symptoms and sometimes arent detected until the cancer gets more serious. According to a study done at UCLA, patients taking Januivahave more than double the risk of developing pancreatic cancer. The longer a patient has been taking the drug, the higher the risk of cancer. Alabama (AL), Alaska (AK), Arizona (AZ), Arkansas (AR), California (CA), Colorado (CO), Connecticut (CT), Delaware (DE), Florida (FL), Georgia (GA), Hawaii (HI), Idaho (ID), Illinois (IL), Indiana (IN), Iowa (IA), Kansas (KS), Kentucky (KY), Louisiana (LA), Maine (ME), Maryland (MD), Massachusetts (MA), Michigan (MI), Minnesota (MN), Mississippi (MS), Missouri (MO), Montana (MT), Nebraska (NE), Nevada (NV), New Hampshire (NH), New Jersey (NJ), New Mexico (NM), New York (NY), North Carolina (NC), North Dakota (ND), Ohio(OH), Oklahoma (OK), Oregon (OR), Pennsylvania (PA), Rhode Island (RI), South Carolina (SC), South Dakota (SD), Tennessee (TN), Texas (TX), Utah (UT), Vermont (VT), Virginia (VI), Washington (WA), Washington DC (DC), West Virginia (WV), Wisconsin (WI), Wyoming (WY) Our lawyers and attorneys can provide information on how to file Januvia lawsuits in the following cities: New York, Chicago, Philadelphia, Detroit, Indianapolis, Columbus, Baltimore, Boston, Seattle, Washington, Milwaukee, Denver, Louisville, Los Angeles, Las Vegas, Nashville, Oklahoma City, Portland, Phoenix, Houston, Tucson, Albuquerque, Atlanta, San Antonio, San Diego, San Francisco, Dallas, Colorado Springs, Arlington, Wichita, Long Continue reading >>

Januvia Lawsuit Says The Drug Caused Pancreatitis

Januvia Lawsuit Says The Drug Caused Pancreatitis

Januvia Lawsuit Says the Drug Caused Pancreatitis A man who took a variety of type-2 diabetes medications alleges in a new Januvia lawsuit that he was diagnosed with pancreatitis, a precursor for pancreatic cancer. The plaintiff, Richard Russo, alleges that he would not have taken the diabetes medication if he knew about this increased risk. When a person develops insulin sensitivity as part of the condition diabetes, his or her pancreas needs to excrete more of it. Januvia, Byetta and Victoza, made variously by Merck, Eli Lilly, Amylin Pharmaceuticals and others, work by increasing the size of the organ. However, in some cases, this can lead to inflammation, also known as acute pancreatitis. The older medications launched before 2010 do not carry warnings regarding the prospect of pancreatitis, which can lead to Januvia pancreatic cancer side effects, as well as similar risks for thyroid cancer with some therapies. This lack of warning has led to a Januvia class action lawsuit investigation and hundreds of personal injury lawsuits filed by patients who took Januvia, Byetta, Victoza, and related statins. Russos Januvia lawsuit argues that the drug labeling is simply inadequate because the earlier drugs do not carry the warnings of thyroid and pancreatic concerns. Moreover, the two classes of drugs still lack any benefit sufficient to tolerate the extreme risk they pose, according to the lawsuit. It also points to the disparity between Victoza and the older medications and how the companies warn of issues likepancreatitis and other Januvia side effects. A 2011 review of the FDAs Adverse Event Reporting System found that pancreatitis occurred between 6 and 10 times more often than in patients using other treatments for their type-2 diabetes. Januvia pancreatic cancer sid Continue reading >>

Januvia Pancreatic Cancer Lawsuits | Janumet Attorney

Januvia Pancreatic Cancer Lawsuits | Janumet Attorney

Januvia & Janumet Pancreatic Cancer Lawsuits We are investigating potential lawsuits throughout the United States for claims on behalf of victims who took the drugs and have suffered from pancreatic cancer. These lawsuits will allege product liability, negligence, and failure to warn claims against Merck & Co., Inc., the manufacturer. These drugs used to treat specific types of diabetes. Januvia is a prescribed pill taken once-daily to help manage blood sugar in adults with type-2 diabetes. Janumet is a prescription used to manage blood sugar in adults with type-2 diabetes mellitus. Type-2 diabetes (also known as adult-onset diabetes and non-insulin dependent diabetes) affects the bodys metabolization of sugar. With type-2 diabetes, the body is either resistant to the effects of insulin or does not manufacture enough insulin. The effect is that the body cannot maintain a normal glucose level. Januvia and Janumet are new classes of drugs known as sitagliptin which are dipeptidyl peptidase-4 (DPP-4) inhibitors or blockers. These DPP-4 blockers help the body to manage blood sugar levels. They increase the amount of insulin manufactured by the pancreas when blood sugars are their highest (usually after eating). They also lower the amount of sugar manufactured by the liver after eating, when the body does not need it. What are the Warning Signs and Dangers of Januvia and Janumet? Januvia and Janumet may cause acute pancreatitis and, as you will see below, pancreatic cancer. On September 25, 2009, the FDA issued a warning to healthcare professionals that the drugs have been associated with 88 cases of acute pancreatitis (including hemorrhagic and necrotizing pancreatitis) by patients using sitagliptin. These 88 cases were found using the FDAs post-market surveillance and occ Continue reading >>

Byetta, Januvia/janumet And Victoza

Byetta, Januvia/janumet And Victoza

Posted in Byetta, Januvia/Janumet and Victoza , Defective Drugs Victoza (liraglutide), an injectable Type II diabetes drug, which works by stimulating insulin production by the pancreas, received approval from the U.S. Food and Drug Administration (FDA) in 2010. When taken in high doses (3 milligrams), Victoza, manufactured by Novo Nordisk, has been shown to help individuals lose weight. The drug suppresses an individuals appetite, as well as decreases the absorption of sugar from the digestive system, and slows movement of food through the digestive system. In essence, the individual is likely to feel fuller for a longer period of time when taking Victoza. Accordingly, individuals began reporting weight loss while taking Victoza. Subsequently, in August 2017, the FDA also approved Victoza to reduce the risk of heart attack, stroke, and cardiovascular death, in adults with Type II diabetes and established cardiovascular disease. Posted in Byetta, Januvia/Janumet and Victoza , Defective Drugs As we have previously reported, safety concerns regarding incretin mimetics (such as Byetta, Januvia/Janumet and Victoza), led to more than a thousand lawsuits being filed across the country. Reports suggest that people taking the medications for the treatment of Type 2 diabetes may be at an increased risk of developing pancreatic cancer. In August 2013, those lawsuits were consolidated in a Multi-District Litigation (MDL), before Judge Anthony J. Battaglia, in the United States District Court for the Southern District of California. The litigation suffered an unexpected setback when, in November 2015, the trial court granted summary judgment, essentially dismissing the claims. Posted in Byetta, Januvia/Janumet and Victoza The U.S. Food and Drug Administration (FDA) warned that Typ Continue reading >>

Januvia, Byetta And Victoza Lawsuits

Januvia, Byetta And Victoza Lawsuits

Judges consolidated lawsuits against the makers of Type 2 diabetes drugs Januvia, Janumet, Byetta and Victoza in MDL No. 2452 in California federal court. Plaintiffs claim drug manufacturers failed to warn about the risk of pancreatic cancer and pancreatitis. Januvia, Byetta and Victoza Lawsuit Facts DefendantsMerck, Amylin, Eli Lilly, Novo Nordisk Prescription drugs Januvia, Janumet, Byetta and Victoza are popular Type 2 diabetes treatments, but reports of dangerous side effects including pancreatitis and pancreatic cancer raised questions about whether the drugs risks outweigh their benefits. People who suffered from these side effects filed lawsuits against the makers of these drugs, Merck (Januvia and Janumet), Amylin and Eli Lilly (Byetta) and Novo Nordisk (Victoza). In May 2013, the U.S. Food and Drug Administration issued safety communications linking the drugs, collectively called incretin mimetics, to serious complications such as pancreatic diseases. The agency also advised the public it was investigating the drugs link to pancreatic cancer. After the agency stated some studies suggested a link between these drugs and pancreatic cancer, the first lawsuits alleging the drugmakers failed to warn about the risk landed in courts across the country. Federal judge in California dismissed all cases in the MDL in '15 In 2013, the United States Judicial Panel on Multidistrict Litigation (JPML) consolidated these cases in California federal court in multidistrict litigation (MDL) number 2452, In Re: Incretin Mimetics Products Liability Litigation. In November 2015, the presiding judge, Anthony J. Battaglia, granted summary judgement in favor of the defendants. Summary judgement means the judge dismissed all cases in the MDL. Plaintiffs attorneys filed an appeal in Sept Continue reading >>

Januvia Type Ii Diabetes Drug From Merck

Januvia Type Ii Diabetes Drug From Merck

The protein DPP-4 is an important part of the digestive and metabolic process. Whats more, it may also be essential in stopping the development of certain cancers and tumors. Studies have shown that blocking this enzyme can lead to a spreading of cancer cells. Incretin drugs like Januvia not only inhibit DPP-4, but have also been shown to increase risks for pancreatitis. This condition, which leads to inflammation of the lining of the pancreas, is considered a major risk factor for pancreatic cancer. In 2009, the FDA first warned that a higher-than-normal number of patients taking Januvia reported suffering pancreatitis. Researchers then identified a link to pancreatic cancer in 2011, when a UCLA study found patients taking Januvia had almost 3 times the risk of the disease. The FDA warned of pre-cancerous findings in incretin drug patients in 2013, and said it would order further testing. Despite additional warnings of Januvia and pancreatic cancer by the American Medical Association and the American Diabetes Association, the FDA concluded in 2013 there wasnt enough evidence to warn patients of pancreatic cancer. Swelling of the liver or gallbladder (lump in abdomen) If you have experienced persistence of any of these symptoms, it is important to talk with your doctor immediately. This is especially true if you are a diabetic or are taking an incretin drug like Januvia. 2018 Januvia Lawsuits and Settlement Amounts Although the FDA has not warned of these pancreatic cancer risks or issued a Januvia recall, courts have ruled that patients and family members affected have the right to seek compensation for their loss. So far, nearly 1,000 plaintiffs have filed incretin drug or Januvia lawsuits after being diagnosed with pancreatic cancer. However, these cases are still a Continue reading >>

Januvia Lawsuit - Byetta Lawsuit; Updates & Settlement Information

Januvia Lawsuit - Byetta Lawsuit; Updates & Settlement Information

Januvia (sitagliptin phosphate) and Byetta (exenatide) are two popular type-2 diabetes medications. Byetta was approved in 2005 and is a glucagon-like peptide-1 agonist (GLP-1 agonist), while Januvia, a DPP-4 inhibitor, first received FDA approval in 2006. Since their approvals, both drugs have reached blockbuster status, raking in millions in profits. But both drugs have also been linked to serious, life-threatening side effects. Merck & Co., the manufacturer of Januvia, and Amylin, Eli Lilly and Bristol-Myers Squibb, the manufacturers of Byetta, have respectively been named in Byetta & Januvia lawsuits. On April 5, 2013, a group of plaintiffs filed a petition for multidistrict litigation (MDL) to be established for cases filed in federal courts where diabetes drugs like Januvia and Byetta are alleged to have caused pancreatic cancer and related injuries. The motion suggests the U.S. District Court for the Southern District of California as an appropriate location for the MDL, where many Januvia and Byetta lawsuits are already pending. MDL which would join multiple Byetta, Victoza, Janumet, and Januvia lawsuit complaints into one court for the purpose of streamlining the pre-trial process, facilitating settlement negotiation, and/or helping to bring the cases to trial in an expedited fashion. Over 50 such cases have been filed in federal courts across the country, with the number expected to grow. Both diabetes medications have a long list of general and minor side effects, but legal complaints typically allege the most serious of Byetta and Januvia side effects . Side effects most often referenced in Januvia lawsuits include: Kidney failure, sometime severe enough to require dialysis Severely low blood sugar, leading to confusion, dizziness, drowsiness, fast heart be Continue reading >>

Januvia Attorneys | Defective Drug Attorneys In New York At Napoli Shkolnik Pllc

Januvia Attorneys | Defective Drug Attorneys In New York At Napoli Shkolnik Pllc

Oral diabetes medications can help to regulate patients blood sugar and insulin levels, an important facet of diabetic health. And while medications like Januvia (active ingredient sitagliptin) are intended to provide patients with a safe way of managing type II diabetes, these drugs pose dangerous health risks. In fact, Januvia has been linked with an increased risk of both pancreatitis and pancreatic cancer. The U.S. Food & Drug Administration (FDA) warns that taking Januvia can lead to inflammation of the pancreas (pancreatitis), which may be severe and lead to death. The symptoms of pancreatitis include: Januvia has also been linked to the development of pancreatic cancer, which has a very low survival rate the five year survival rate for pancreatic cancer at stage IA is 14 percent; at stage IV, the survival rate is only one percent. Another side effects of Januvia that patients should be aware of is the risk of developing kidney problems, which may be severe enough to warrant dialysis. When Januvia Causes Patient Injury and Death Taking Januvia can cause serious patient injury and death. When this occurs, a patient has the right to file a lawsuit directly against Januvias manufacturer, Merck & Co. alleging that the company failed to conduct proper testing, failed to issue a proper warning about the risks of developing pancreatitis, and manufactured a defective drug unsafe for patient use. Do I Have the Right to Take Legal Action? If you have been harmed as a direct result of taking Januvia, a consultation with a pharmaceutical litigation attorney can help you understand whether or not you have a cause of action against Merck & Co. At Napoli Shkolnik, PLLC, our experienced defective drug attorneys can also help you to estimate how much your case may be worth, and a Continue reading >>

More in diabetes